Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation

International Journal of Cardiology

Volumn 131, Issue 2, 2009, Pages 204-211

  Dijksman, L M ^a   Hirsch, A ^a   Windhausen, F ^a   Asselman, F F ^a   Tijssen, J G P ^a   Dijkgraaf, M G W ^a   de Winter, R J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Revascularization; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 57549089116     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.10.019     Document Type: Article

References (18)

1. Boden W.E., and McKay R.G. Optimal treatment of acute coronary syndromes-an evolving strategy. N Engl J Med 344 (2001) 1939-1942
2. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
3. Mehta S.R., Cannon C.P., Fox K.A., et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
4. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 89 (1994) 1545-1556
5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715
6. Boden W.E., O'Rourke R.A., Crawford M.H., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 338 (1998) 1785-1792
7. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
8. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 360 (2002) 743-751
9. Janzon M., Levin L.A., and Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J 23 (2002) 31-40
10. Mahoney E.M., Jurkovitz C.T., Chu H., et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288 (2002) 1851-1858
11. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 (2005) 1095-1104
12. Oostenbrink J.B., Koopmanschap M.A., and Rutten F.F. Guidelines for cost calculations, methods and recommended prices for economic evaluations in health care [in Dutch] (2000), College voor Zorgverzekeringen, Amstelveen
13. Central Medical Pharmaceutical Committee of the National Health Service Council. Farmaceutisch Kompas (2005), National Health Service Council, Utrecht
14. Briggs A.H., and O'Brien B.J. The death of cost-minimization analysis?. Health Econ 10 (2001) 179-184
15. Barber J.A., and Thompson S.G. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19 (2000) 3219-3236
16. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. Methods for the economic evaluation of health care programmes. Third Edition (2005), Oxford University Press, New York
17. Fenwick E., O'Brien B.J., and Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 13 (2004) 405-415
18. Cannon C.P., Braunwald E., Mccabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504